Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Интернет]. 31 декабрь 2025 г. [цитируется по 14 апрель 2026 г.];40(2):251-62. доступно на: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001